157 related articles for article (PubMed ID: 38465776)
21. Factors involved in phenoconversion of CYP3A using 4β-hydroxycholesterol in stable kidney transplant recipients.
Suzuki Y; Muraya N; Fujioka T; Sato F; Tanaka R; Matsumoto K; Sato Y; Ohno K; Mimata H; Kishino S; Itoh H
Pharmacol Rep; 2019 Apr; 71(2):276-281. PubMed ID: 30826567
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant.
Hibino H; Sakiyama N; Makino Y; Makihara-Ando R; Horinouchi H; Fujiwara Y; Kanda S; Goto Y; Yoshida T; Okuma Y; Shinno Y; Murakami S; Hashimoto H; Akiyoshi T; Imaoka A; Ohe Y; Yamaguchi M; Ohtani H
Eur J Clin Pharmacol; 2022 Apr; 78(4):613-621. PubMed ID: 35039908
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice.
Nitta SI; Hashimoto M; Kazuki Y; Takehara S; Suzuki H; Oshimura M; Akita H; Chiba K; Kobayashi K
AAPS J; 2018 Apr; 20(3):61. PubMed ID: 29858698
[TBL] [Abstract][Full Text] [Related]
24. Relationships between concomitant biologic DMARDs and prednisolone administration and blood tacrolimus exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients.
Naito T; Ohshiro J; Sato H; Torikai E; Suzuki M; Ogawa N; Kawakami J
Clin Biochem; 2019 Jul; 69():8-14. PubMed ID: 31077643
[TBL] [Abstract][Full Text] [Related]
25. Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol.
Nylén H; Sergel S; Forsberg L; Lindemalm S; Bertilsson L; Wide K; Diczfalusy U
Eur J Clin Pharmacol; 2011 Jul; 67(7):715-22. PubMed ID: 21246351
[TBL] [Abstract][Full Text] [Related]
26. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.
Josephson F; Bertilsson L; Böttiger Y; Flamholc L; Gisslén M; Ormaasen V; Sönnerborg A; Diczfalusy U
Eur J Clin Pharmacol; 2008 Aug; 64(8):775-81. PubMed ID: 18458892
[TBL] [Abstract][Full Text] [Related]
27. A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys.
Tahara H; Watanabe M; Hasegawa M
Biopharm Drug Dispos; 2019 Feb; 40(2):81-93. PubMed ID: 30724384
[TBL] [Abstract][Full Text] [Related]
28. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4.
Bodin K; Bretillon L; Aden Y; Bertilsson L; Broomé U; Einarsson C; Diczfalusy U
J Biol Chem; 2001 Oct; 276(42):38685-9. PubMed ID: 11514559
[TBL] [Abstract][Full Text] [Related]
29. CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.
Suzuki Y; Fujioka T; Sato F; Matsumoto K; Muraya N; Tanaka R; Sato Y; Ohno K; Mimata H; Kishino S; Itoh H
Br J Clin Pharmacol; 2015 Dec; 80(6):1421-8. PubMed ID: 26773964
[TBL] [Abstract][Full Text] [Related]
30. Identification and in vivo detection of side-chain hydroxylated metabolites of 4β-hydroxycholesterol.
Roumain M; Guillemot-Legris O; Ameraoui H; Alhouayek M; Muccioli GG
J Steroid Biochem Mol Biol; 2023 Nov; 234():106376. PubMed ID: 37604319
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients.
Habtewold A; Amogne W; Makonnen E; Yimer G; Nylén H; Riedel KD; Aderaye G; Bertilsson L; Burhenne J; Diczfalusy U; Aklillu E
Pharmacogenomics J; 2013 Dec; 13(6):484-9. PubMed ID: 23089673
[TBL] [Abstract][Full Text] [Related]
32. Assessment of induced CYP3A activity in pregnant women using 4β-hydroxycholesterol: Cholesterol ratio as an appropriate metabolic marker.
Kim AH; Kim B; Rhee SJ; Lee Y; Park JS; Lee SM; Kim SM; Lee S; Yu KS; Jang IJ; Cho JY
Drug Metab Pharmacokinet; 2018 Jun; 33(3):173-178. PubMed ID: 29759884
[TBL] [Abstract][Full Text] [Related]
33. Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy.
Wide K; Larsson H; Bertilsson L; Diczfalusy U
Br J Clin Pharmacol; 2008 May; 65(5):708-15. PubMed ID: 18279471
[TBL] [Abstract][Full Text] [Related]
34. Quantitation of P450 3A4 endogenous biomarker - 4β-hydroxycholesterol - in human plasma using LC/ESI-MS/MS.
Huang MQ; Lin W; Wang W; Zhang W; Lin ZJ; Weng N
Biomed Chromatogr; 2014 Jun; 28(6):794-801. PubMed ID: 24861746
[TBL] [Abstract][Full Text] [Related]
35. 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin.
Diczfalusy U; Kanebratt KP; Bredberg E; Andersson TB; Böttiger Y; Bertilsson L
Br J Clin Pharmacol; 2009 Jan; 67(1):38-43. PubMed ID: 19006545
[TBL] [Abstract][Full Text] [Related]
36. CYP3A Activity in End-of-Life Cancer Patients Measured by 4β-Hydroxycholesterol/cholesterol Ratio, in Men and Women.
Bergström H; Helde Frankling M; Klasson C; Lövgren Sandblom A; Diczfalusy U; Björkhem-Bergman L
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572915
[TBL] [Abstract][Full Text] [Related]
37. Clinical Evaluation Based on a New Approach to Improve the Accuracy of 4β-Hydroxycholesterol Measurement as a Biomarker of CYP3A4 Activity.
Taya Y; Mizunaga M; Nakao S; Jutanom M; Shimizu N; Nomura Y; Nakagawa K
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838563
[TBL] [Abstract][Full Text] [Related]
38. Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation.
Suzuki Y; Itoh H; Sato F; Kawasaki K; Sato Y; Fujioka T; Sato Y; Ohno K; Mimata H; Kishino S
J Lipid Res; 2013 Sep; 54(9):2568-72. PubMed ID: 23833241
[TBL] [Abstract][Full Text] [Related]
39. Formation of CYP3A-specific metabolites of ibrutinib in vitro is correlated with hepatic CYP3A activity and 4β-hydroxycholesterol/cholesterol ratio.
Lee J; Fallon JK; Smith PC; Jackson KD
Clin Transl Sci; 2023 Feb; 16(2):279-291. PubMed ID: 36350327
[TBL] [Abstract][Full Text] [Related]
40. Effect of Statin Treatment on Plasma 4β-Hydroxycholesterol Concentrations.
Björkhem-Bergman L; Nylén H; Eriksson M; Parini P; Diczfalusy U
Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):499-502. PubMed ID: 26617265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
